The Current Treatment Landscape of Oral SERDs in Metastatic Breast Cancer
Panelists discuss their overall perceptions of oral selective estrogen receptor degraders (SERDs) and their impact on the treatment landscape and share their experiences with elacestrant in clinical practice.
Video Player is loading.
Play Video
Play
Mute
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
Seek to live, currently behind liveLIVE
Remaining Time -0:00
1x
Playback Rate
2x
1.75x
1.5x
1.25x
1x, selected
0.75x
0.5x
Chapters
Chapters
Descriptions
descriptions off, selected
Captions
captions and subtitles off, selected
Audio Track
Fullscreen
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Reset restore all settings to the default valuesDone